AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$ARQT

Matsuda Masaru sold $250K of ARQT

Matsuda Masaru (See Remarks) sold 9,989 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.25M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Matsuda Masaru
Published Sep 10, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

Provides transparency; investors may monitor future insider activity.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming clinical data could offset sale impact.

Relevance 3/10Novelty 3/10Timing: post‑market filing on Sep 10, 2026

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Officer Matsuda Masaru sold 9,989 ARQT shares for $249,986 via a 10b5-1 plan.

Expected impact

No material move expected.

Evidence & confidence

Sale size (~$250k) is small relative to market cap; insider is using pre‑arranged plan.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only.

Global

Low

Counterpoint

What could challenge this read

Insider sale could signal concerns, but size is trivial.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Officer
    Matsuda Masaru

    Company officer executing a 10b5-1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

AUG 5
$ARQTHigh

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min